Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Aromasin Cleared For Early Breast Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer's oncologic Aromasin (exemestane) received approval Oct. 5 for the adjuvant treatment of early breast cancer in patients crossing over from tamoxifen therapy

Pfizer's oncologic Aromasin (exemestane) received approval Oct. 5 for the adjuvant treatment of early breast cancer in patients crossing over from tamoxifen therapy.

Aromasin's additional indication is for "adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer following two to three years of tamoxifen for a completion of five consecutive years of adjuvant hormonal therapy," Pfizer said.

Pfizer's Intergroup Exemestane Study found a 31% reduced risk of cancer recurrence in patients switching to Aromasin tablets versus those remaining on tamoxifen.

Aromasin was previously approved for treatment of advanced breast cancer in patients whose disease progressed following tamoxifen therapy.

Novartis is studying Femara (letrozole) in patients crossing over from tamoxifen, with results expected in 2008. The firm has already submitted the breast cancer therapy for an early adjuvant claim (1 (Also see "Novartis Submits Femara For Early Adjuvant Treatment Of Breast Cancer" - Pink Sheet, 11 Jul, 2005.)).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS061217

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel